Dear Editor,
Almost all reports on liver injury in patients with 2019 coronavirus disease (COVID-19) found blood liver tests to be frequently abnormal, especially in patients with more severe disease, but with substantial heterogeneity [1]. Moreover, blood liver tests’ abnormalities were frequently thought to be of doubtful clinical value.
Most studies have described blood liver tests in a single time point, usually at inclusion [2, 3]. Therefore, we used our case series of the first 20 consecutive patients with COVID-19 admitted to the intensive care unit (ICU) at Curry Cabral Hospital in Lisbon, Portugal, from March 10, 2020, onwards, to describe the temporal evolution of blood liver tests.
Median (interquartile range (IQR)) age was 67 (52–74) years with 18 (90%) males (Table 1). Median (IQR) time from symptom onset to hospital admission was 7.5 (5.5–8.5) days, and median time from hospital admission to ICU admission was 1.1 (0.7–2.1) days. All patients required invasive mechanical ventilation on ICU admission. Median (IQR) sequential organ failure assessment (SOFA) score on ICU admission and peak was 8 (7–9) and 9 (8–11), respectively. As of April 10, following a median (IQR) of 21.5 (11.2–25.4) days post ICU admission, 3 (15%) patients died of multi-organ failure, 14 (70%) were discharged to the ward, and 3 (15%) remained in the ICU.
Table 1.
Baseline characteristics and outcomes of patients
Characteristic | Median (IQR) or n (%) |
---|---|
Age (years) | 67 (52–74) |
Sex (male) | 18 (90%) |
BMI (kg/m2) | 29 (26–32) |
Parameters on ICU admission | |
PaO2/FiO2 | 138 (128–163) |
Lactate (mmol/L) | 1.1 (0.8–1.2) |
Creatinine (mg/dL) | 1.11 (1.04–1.26) |
Organ support during ICU stay | |
Invasive mechanical ventilation | 20 (100%) |
Vasopressors | 19 (95%) |
Renal replacement therapy | 7 (35%) |
SOFA score | |
ICU admission | 8 (7–9) |
Peak | 9 (8–11) |
ICU discharge | 3 (2–6) |
APACHEII score | 18 (14–21) |
ICU mortality | 3 (15%) |
Hospital mortality | 3 (15%) |
ICU length of stay (days) | 10.3 (8.0–12.3) |
Hospital length of stay (days) | 22.4 (14.1–26.7) |
IQR interquartile range, BMI body mass index, PaO2/FiO2 oxygen partial pressure/oxygen inspired fraction, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, APACHEII Acute Physiology and Chronic Health Evaluation II
No patient had documented liver disease prior to hospitalization. During the first 10 days post ICU admission, all patients had at least one abnormal blood liver test. Overtime, only median gamma-glutamiltranspeptidase (GGT), alanine transferase (ALT), and aspartate transferase (AST) showed any increase from upper limit of normal (ULN) and only median GGT had a ≥ 3 fold increase from ULN (Table 2). Median peak GGT was on day 8 post ICU admission. Patients with peak C-reactive protein ≥ 250 mg/L (day 4 post ICU admission) had higher but non-significant median peak GGT (298 vs. 125 IU/L), ALT (101 vs. 42 IU/L), or AST (72 vs. 57 IU/L) than others (P > 0.50 for all comparisons).
Table 2.
Temporal evolution of median levels of blood tests
Test (upper limit of normal) | H adm | ICU adm | D2 | D3 | D4 | D5 | D6 | D7 | D8 | D9 | D10 |
---|---|---|---|---|---|---|---|---|---|---|---|
INR (≤ 1.2) | 1.18 | 1.17 | 1.20 | 1.16 | 1.17 | 1.18 | 1.17 | 1.15 | 1.17 | 1.17 | 1.16 |
Bilirubin (≤ 1.2 mg/dL) | 0.65 | 0.80 | 1.01 | 1.16 | 0.80 | 0.86 | 1.05 | 0.92 | 1.15 | 0.87 | 0.97 |
ALP (≤ 150 IU/L) | 61 | 59 | 61 | 74 | 83 | 89 | 101 | 95 | 116 | 125 | 111 |
GGT (≤ 64 IU/L) | 55 | 52 | 53 | 66 | 92 | 73 | 102 | 214 | 237 | 211 | 225 |
ALT (≤ 55 IU/L) | 31 | 30 | 33 | 31 | 43 | 48 | 56 | 67 | 82 | 55 | 72 |
AST (≤ 34 IU/L) | 51 | 51 | 51 | 44 | 49 | 57 | 69 | 62 | 60 | 53 | 46 |
CRP (≤ 5 mg/L) | 176 | 207 | 239 | 257 | 271 | 258 | 198 | 153 | 97 | 76 | 74 |
H adm hospital admission, ICU adm intensive care unit admission, INR international normalized ratio, ALP alkaline phosphatase, GGT gamma-glutamiltranspeptidase, ALT alanine aminotransferase, AST aspartate aminotransferase, CRP C-reactive protein
In our case series, liver injury was frequent but generally transient and non-severe. While synthetic function was largely preserved, late cholestasis was frequently observed. Cholestasis may have been associated to the critical illness itself (inflammation), parenteral nutrition (only 2 patients required parenteral nutrition), or drug toxicity (all patients were on antibiotics, for example ceftriaxone, amoxicillin-clavulanate, or azithromycin) [4, 5]. While cholestasis could have been multifactorial, the differential diagnosis was not easy to perform with precision. Overall, attention to modifiable factors, such as control of inflammation, timing of parenteral nutrition, and avoiding drugs with worse liver toxicity profile, may be important to prevent cholestasis progression in these patients. Further studies are needed to understand liver injury in critically ill patients with COVID-19, especially if there is any direct viral effect on the liver cells.
Acknowledgements
Not applicable.
Abbreviations
- ALT
Alanine transferase
- ALP
Alkaline phosphatase
- AST
Aspartate transferase
- COVID-19
2019 coronavirus disease
- CRP
C-reactive protein
- ICU
Intensive care unit
- IMV
Invasive mechanical ventilation
- INR
International normalized ratio
- IQR
Interquartile range
- GGT
Gamma-glutamiltranspeptidase
Authors’ contributions
FSC collected, analyzed, and interpreted the data. FSC drafted the manuscript. The authors read and approved the final manuscript.
Funding
The authors declare that they have no funding source.
Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to confidentiality but are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
The ethics committee at Curry Cabral Hospital, Lisbon, Portugal, waived the need for consent because the study was observational.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Filipe S. Cardoso, Email: filipe_sousacardoso@hotmail.com
Rui Pereira, Email: rui.pereira@mail.com.
Nuno Germano, Email: nuno.m.germano@gmail.com.
References
- 1.Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020. 10.1016/S2468-1253(20)30084-4. [DOI] [PMC free article] [PubMed]
- 2.Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020. 10.1001/jama.2020.4326. [DOI] [PMC free article] [PubMed]
- 3.Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region - case series. N Engl J Med. 2020. 10.1056/NEJMoa2004500. [DOI] [PMC free article] [PubMed]
- 4.Vanwijngaerden YM, Wauters J, Langouche L, Vander Perre S, Liddle C, Coulter S, et al. Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology. 2011;54(5):1741–1752. doi: 10.1002/hep.24582. [DOI] [PubMed] [Google Scholar]
- 5.Jenniskens M, Langouche L, Van den Berghe G. Cholestatic alterations in the critically ill: some new light on an old problem. Chest. 2018;153(3):733–743. doi: 10.1016/j.chest.2017.08.018. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets generated and/or analyzed during the current study are not publicly available due to confidentiality but are available from the corresponding author on reasonable request.